Tumor neoantigens: building a framework for personalized cancer immunotherapy

It is now well established that the immune system can recognize developing cancers and that therapeutic manipulation of immunity can induce tumor regression. The capacity to manifest remarkably durable responses in some patients has been ascribed in part to T cells that can (a) kill tumor cells directly, (b) orchestrate diverse antitumor immune responses, (c) manifest long-lasting memory, and (d) display remarkable specificity for tumor-derived proteins. This specificity stems from fundamental differences between cancer cells and their normal counterparts in that the former develop protein-altering mutations and undergo epigenetic and genetic alterations, resulting in aberrant protein expression. These events…

• CR
  Cancer Research Institute
• BS
  Bristol-Myers Squibb
• AJ
  Alvin J. Siteman Cancer Center
• NI
  National Institutes of Health

  Awards: U54 HG003079, HG003079
• SU
  Stand Up To Cancer
• NC
  National Cancer Institute

  Awards: U54 HG003079, U01 CA141541